Western Slope residents watch rare Bundibugyo Ebola outbreak in Congo

What does a rare strain of Ebola in the Democratic Republic of Congo mean for the folks who live here on the Western Slope?

It means keeping an eye on the airport. It means understanding that a virus in a conflict zone thousands of miles away doesn't just stay there. And it means knowing that when health officials talk about "scale and speed," they aren't using buzzwords — they’re describing a race against time that affects how fast supplies move and how quickly we might need to worry about travelers bringing it back.

The World Health Organization’s top official, Tedros Adhanom Ghebreyesus, said Tuesday that he is “deeply concerned about the scale and speed of the epidemic.”

He’s looking at a rare type of Ebola called Bundibugyo. It’s not the one we hear about most often. It has no approved medicines or vaccines. And right now, it’s moving through eastern Congo, specifically the Ituri province, with 134 suspected deaths and more than 500 suspected cases.

The question is whether this outbreak will stay contained in the dense forests and rebel-held territories of the DRC, or if it will jump to major urban centers and spread faster than anyone expects.

So far, the answer is a mix of both.

Cases have been confirmed in Bunia, the provincial capital. They’ve also popped up in Uganda, just across the border. Two confirmed cases in Kampala, the Ugandan capital, including a death, were linked to people who had traveled from Congo.

That’s the speed part. Tedros pointed to cases emerging in urban areas, healthcare workers dying in the trenches, and significant population movement. That’s the scale.

But here’s the catch: we don’t have a silver bullet yet.

Jean-Jacques Muyembe, a virus expert at the National Institute of Biomedical Research, said Congo is expecting shipments from the United States and Britain of an experimental vaccine. It was developed by researchers at Oxford. But it’s not a cure-all for this specific strain, and it’s not available tomorrow.

“We will administer the vaccine and see who develops the disease,” Muyembe said.

Experts say such efforts would take time. Dr. Anne Ancia, who heads the WHO team in Congo, put a concrete number on it. The Ervebo vaccine, which is used against a different type of Ebola, is being considered. But anything approved for use would take two months to become available.

“I don’t see that in two months we will be done with this outbreak,” Ancia said.

Two months. That’s a long time in an epidemic.

The logistics are complicated by the fact that parts of eastern Congo are in the hands of armed rebels. Sending aid isn’t just about getting a plane to land; it’s about getting it through checkpoints and into areas where fighting can flare up at any moment.

For now, the U.S. Centers for Disease Control and Prevention and the Africa Centers for Disease Control aren’t on the ground yet. But others are. Doctors Without Borders and the Red Cross are already there. UNICEF has sent an initial 16 tons of relief supplies to Bunia.

Hela Skhiri, UNICEF’s Bunia bureau chief, said those supplies — mainly disinfectants, soaps, personal protective equipment, and water purification tablets, are being distributed according to need across three treatment centers in Ituri province.

It’s a stopgap measure. It’s not a solution.

The virus spread undetected for weeks after the first known death in Bunia. Why? Because authorities were testing for the more common types of Ebola and came up negative. They were looking for the wrong thing.

Noëla Lumo, a resident in Bunia, summed up the anxiety on the ground. She was wearing a fabric mask while health workers in full protective gear moved around her.

“I know the consequences of Ebola, I know what it’s like,” Lumo said.

It’s a simple statement. It cuts through the technical jargon about viral load and transmission vectors. It’s about fear. It’s about knowing that if you get it, the stakes are high.

The WHO has declared this outbreak a public health emergency of international concern. That requires a coordinated response. Resources are being rushed to two affected provinces near Uganda. But the question remains whether the international community can move fast enough to contain a rare strain in a region where war and disease are already intertwined.

As Ancia noted, authorities still haven’t identified “patient zero.” Without knowing where it started, it’s harder to predict where it’s going.

The figures support that concern. 134 deaths. More than 500 cases. And a vaccine that’s still in the pipeline.

The outcome depends on whether the experimental shots from Oxford can slow the spread, or if the Bundibugyo virus will continue to outpace our ability to track it. For now, the world is watching, waiting, and shipping.